InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,131.60
(
-0.23%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.35
(
-0.15%
)
Bitcoin
60,618.26
(
-0.32%
)
Post# of 252389
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 251779

Thursday, 06/06/2024 6:24:29 PM

Thursday, June 06, 2024 6:24:29 PM

Post# of 252389
VRBPAC recommends JN.1 target for fall COVID vaccines:

https://thehill.com/policy/healthcare/4706149-fda-panel-picks-jn-1-subvariant-for-fall-covid-vaccines/

The expert advisory panel for the Food and Drug Administration (FDA) unanimously voted Wednesday in favor of selecting the JN.1 COVID-19 subvariant to be targeted by the next round of COVID-19 vaccines this fall.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) was asked if it would recommended a monovalent vaccine that targets the JN.1 omicron subvariant for the 2024-2024 COVID vaccines. All 16 voting members voted in favor of selecting this lineage for the fall.

This decision is positive for NVAX insofar as NVAX is already manufacturing a JN.1 vaccine and it wouldn’t have been able to change strains in time for the 2024 fall vaccination season.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up